| Wesley Sivak, | |
|
3550 Terrace St, Scaife Hall, Suite 6b, Pittsburgh, PA 15213-2500 | |
| (412) 383-8082 | |
| (412) 383-8986 |
| Full Name | Wesley Sivak |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 16 Years |
| Location | 3550 Terrace St, Pittsburgh, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629209184 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | MT196047 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grant Medical Center | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
Agilent Technologies Inc. today announced that a group of researchers from the University of California, Davis, has made a significant discovery: human breast milk contains an unexpected abundance of sugars that coats the lining of infants' intestines, protecting it from noxious bacteria. Results of the research, which used Agilent technology, were published in this month's Proceedings of the National Academy of Sciences of the United States of America.
The U.S. Food and Drug Administration today allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections.
Impel NeuroPharma, a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier (BBB) using direct nose-to-brain delivery, today announced a set of important milestones in its drive to commercialize its POD technology.
Ludwig researchers Arshad Desai and Christopher Campbell, a post-doctoral fellow in his laboratory, were conducting an experiment to parse the molecular details of cell division about three years ago, when they engineered a mutant yeast cell as a control that, in theory, had no chance of surviving. Apparently unaware of this, the mutant thrived.
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
› Verified 8 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
Agilent Technologies Inc. today announced that a group of researchers from the University of California, Davis, has made a significant discovery: human breast milk contains an unexpected abundance of sugars that coats the lining of infants' intestines, protecting it from noxious bacteria. Results of the research, which used Agilent technology, were published in this month's Proceedings of the National Academy of Sciences of the United States of America.
The U.S. Food and Drug Administration today allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections.
Impel NeuroPharma, a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier (BBB) using direct nose-to-brain delivery, today announced a set of important milestones in its drive to commercialize its POD technology.
Ludwig researchers Arshad Desai and Christopher Campbell, a post-doctoral fellow in his laboratory, were conducting an experiment to parse the molecular details of cell division about three years ago, when they engineered a mutant yeast cell as a control that, in theory, had no chance of surviving. Apparently unaware of this, the mutant thrived.
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wesley Sivak, 3550 Terrace St, Scaife Hall, Suite 6b, Pittsburgh, PA 15213-2500 Ph: (412) 383-8082 | Wesley Sivak, 3550 Terrace St, Scaife Hall, Suite 6b, Pittsburgh, PA 15213-2500 Ph: (412) 383-8082 |
News Archive
Agilent Technologies Inc. today announced that a group of researchers from the University of California, Davis, has made a significant discovery: human breast milk contains an unexpected abundance of sugars that coats the lining of infants' intestines, protecting it from noxious bacteria. Results of the research, which used Agilent technology, were published in this month's Proceedings of the National Academy of Sciences of the United States of America.
The U.S. Food and Drug Administration today allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections.
Impel NeuroPharma, a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier (BBB) using direct nose-to-brain delivery, today announced a set of important milestones in its drive to commercialize its POD technology.
Ludwig researchers Arshad Desai and Christopher Campbell, a post-doctoral fellow in his laboratory, were conducting an experiment to parse the molecular details of cell division about three years ago, when they engineered a mutant yeast cell as a control that, in theory, had no chance of surviving. Apparently unaware of this, the mutant thrived.
ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.
› Verified 8 days ago
Dr. James L Fernau, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 Cliffmine Rd, Suite 120, Pittsburgh, PA 15275 Phone: 412-446-0391 | |
Oluseyi Aliu, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 320 E North Ave Ste 401, Pittsburgh, PA 15212 Phone: 412-359-4352 | |
Ryan Taylor Marshall Mitchell, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3550 Terrace St, Scaife Hall Ste 6b, Pittsburgh, PA 15213 Phone: 412-647-3087 | |
Robert H Kang, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4815 Liberty Ave Ste 425, Pittsburgh, PA 15224 Phone: 412-578-1849 Fax: 412-578-0259 | |
Michael J White, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 320 E North Ave Ste 401, Pittsburgh, PA 15212 Phone: 412-359-4352 Fax: 412-359-8285 | |
Debra Anne Bourne, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3550 Terrace St, 683 Scaife Hall, Pittsburgh, PA 15213 Phone: 412-383-8986 | |
Dalit Amar, MD Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3380 Boulevard Of The Allies, Pittsburgh, PA 15213 Phone: 412-641-3960 Fax: 412-641-1149 |